Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucose Monitoring, Other Apr 19 | 2023Abbott Q1 '23 Earnings; Eversense 365-Day Sensor Inserted Into First Pediatric Patient; Esperion Partners With Currax for Nexletol/Nexlizet Promotion; Zucara ZT-01 Ph2 T1DM IND ClearedPurchase Blast
$599
Posted in: Other Apr 19 | 2023Resmetirom Receives Breakthrough Therapy Designation; Tiziana Initiates Foralumab T1DM Program; Teladoc Expands Provider-Based Care; J&J Q1 '23 EarningsPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Apr 17 | 2023Lilly Invests $1.6B in Indiana Manufacturing; Dexcom and Abbott Highlight Medicare CGM Coverage Expansion; Tandem Announces Positive Control-IQ Meta-AnalysisPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA + Basal, Glucose Monitoring Apr 14 | 2023Lilly Completes SURMOUNT-2 Trial; FDA Clears Libre 3 Reader; Novo Initiates Ph3 Icodec + Semaglutide Treatment Intensification TrialPurchase Blast
$599
Posted in: GLP-1RA, Other Apr 13 | 2023Novo Raises 2023 Guidance; Sana Biotechnology Appoints New R&D Leaders and Announces Publication of Pre-Clinical DataPurchase Blast
$599
Posted in: Dual/triple agonist, Other Apr 12 | 2023New Tirzepatide Injection Device Trial; Novo Partners with Aspect Biosystems; Sanofi’s Provention Bio Acquisition Regulatory Issue; Glooko Partners with HediaPurchase Blast
$599
Posted in: GLP-1RA Apr 11 | 2023FENIX Analysis: Lilly Oral GLP-1RA Pivotal ProgramPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Apr 04 | 2023Lannett Announces Positive Pivotal Bs-Glargine Results; Mark Cuban’s Pharmacy Offers Janssen’s Invokana; Diamyd Partners with JDRF for Ph3 Diamyd T1DM DevelopmentPurchase Blast
$599
Posted in: Other Apr 03 | 2023NeuroBo Submits NASH IND; New Akebia Vadadustat Data; Arrowhead Earns $30M Milestone Payment from GSKPurchase Blast
$599
Posted in: GLP-1RA, Other Mar 31 | 2023Wegovy and Entresto Receive Positive CHMP Opinions for Pediatric Indication ExtensionsPurchase Blast
$599
Posted in: Other Mar 30 | 2023Akero to Initiate Ph3 NASH Program; Bigfoot Acquires Insulin Titration Algorithm; GSK Collaborates with PathAI in NASHPurchase Blast
$599
Posted in: GLP-1RA, Other Mar 29 | 2023FDA Releases Framework for Use of Digital Health Technology in Clinical Trials; New Ph2 Dapiglutide Obesity TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Mar 28 | 2023Viking Announces Positive Ph1 GLP-1/GIP Dual Agonist Topline Results and Initiates Oral Formulation Development; Zealand Ph1a Amylin Analog Results; Biomea Ph2 Menin Inhibitor ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, Other Mar 27 | 2023Mounjaro Obesity Indication Filed in EU; March CHMP Agenda; Vertex Announces T1DM Licensing Agreement with CRISPR; Sanofi Helps Dario Secure Top-Ten PBM ContractPurchase Blast
$599
Posted in: GLP-1RA Mar 24 | 2023Positive High-Dose Oral Semaglutide Topline ResultsPurchase Blast
$599
Posted in: Other Mar 22 | 202389bio Positive Ph2b Pegozafermin NASH Data; Novartis Discontinues Inclisiran UK Primary Prevention Trial; Novo Nordisk Partners with Dewpoint Therapeutics; Evkeeza Receives Pediatric ApprovalPurchase Blast
$599
Posted in: GLP-1RA Mar 21 | 2023Altimmune Ph2 Obesity and Ph1b T2DM Pemvidutide DataPurchase Blast
$599
Posted in: Glucose Monitoring, Other Mar 21 | 2023Senseonics Q4 ’22 Earnings and CGM Investor Event; OrsoBio Doses First Patient in Ph2 TLC-3595 Trial for Insulin ResistancePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Mar 17 | 2023Sanofi Follows Lilly and Novo's Insulin Price CutsPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
